{
"ranked_hypotheses": [
{
"title": "Sleep-Dependent Glymphatic Clearance Expands the Therapeutic Window by Reducing Extracellular Tau Burden",
"description": "Enhancing glymphatic clearance reduces extracellular tau 'load' through sleep-dependent waste removal mechanisms, decreasing trans-synaptic transfer probability without directly disrupting synaptic transmission machinery. Repurposed orexin receptor antagonists (suvorexant, lemborexant) offer rapid clinical translation with established safety profiles.",
"target_gene": "AQP4, orexin receptor (HCRTR1/2)",
"dimension_scores": {
"evidence_strength": 0.78,
"novelty": 0.65,
"feasibility": 0.85,
"therapeutic_potential": 0.72,
"mechanistic_plausibility": 0.75,
"druggability": 0.88,
"safety_profile": 0.92,
"competitive_landscape": 0.70,
"data_availability": 0.80,
"reproducibility": 0.78
},
"composite_score": 0.78,
"evidence_for": [
{"claim": "Sleep deprivation increases interstitial tau and accelerates propagation", "pmid": "31437569"},
{"claim": "AQP4 deletion impairs glymphatic clearance and worsens tauopathy", "pmid": "29991827"},
{"claim": "Natural sleep increases convective clearance by 60%", "pmid": "31437569"},
{"claim": "Orexin receptor antagonists enhance glymphatic function", "pmid": "31857442"}
],
"evidence_against": [
{"claim": "Glymphatic enhancement may be insufficient as monotherapy", "pmid": null},
{"claim": "Mechanism is indirect; does not block intracellular propagation", "pmid": null}
]
},
{
"title": "Conformational-Selective Blocking of Tau Uptake Reveals Therapeutic Window in Neuronal Re-entry",
"description": "Pathological tau oligomers enter neurons via LRP1 and HSPG receptors with higher affinity than monomeric tau. Conformational-selective VHHs or antibodies could block pathological uptake while sparing essential receptor functions. Highest therapeutic index potential among direct propagation inhibitors.",
"target_gene": "LRP1, HSPG (SDC3, GPC1), tau conformations",
"dimension_scores": {
"evidence_strength": 0.72,
"novelty": 0.80,
"feasibility": 0.68,
"therapeutic_potential": 0.75,
"mechanistic_plausibility": 0.70,
"druggability": 0.62,
"safety_profile": 0.78,
"competitive_landscape": 0.72,
"data_availability": 0.65,
"reproducibility": 0.68
},
"composite_score": 0.71,
"evidence_for": [
{"claim": "LRP1 mediates tau uptake and propagation", "pmid": "32205366"},
{"claim": "Conformational antibodies differentiate pathological from physiological tau", "pmid": "29241305"},
{"claim": "HSPG inhibition blocks tau uptake without affecting most endocytic pathways", "pmid": "30626874"},
{"claim": "Monomeric extracellular tau has unclear physiological function", "pmid": "29130380"}
],
"evidence_against": [
{"claim": "Pathological conformation is not a single stable entity across tauopathies", "pmid": null},
{"claim": "Receptor redundancy undermines single-receptor targeting; LRP1 knockdown reduces but does not eliminate uptake", "pmid": "32205366"},
{"claim": "Conformational antibodies have failed in clinical trials due to brain penetration and specificity issues", "pmid": null}
]
},
{
"title": "Critical Period Hypothesis: The Therapeutic Window Closes When Neuronal Homeostasis is Irreversibly Disrupted",
"description": "During early disease phases, neurons tolerate partial propagation inhibition; the therapeutic window is wide. Biomarker-defined staging (NfL, p-tau217) identifies patients within the open window. Functions as a clinical development framework rather than direct therapeutic target.",
"target_gene": "NfL, p-tau217, p-tau231, ATF4, TOMM40",
"dimension_scores": {
"evidence_strength": 0.65,
"novelty": 0.58,
"feasibility": 0.72,
"therapeutic_potential": 0.68,
"mechanistic_plausibility": 0.55,
"druggability": 0.45,
"safety_profile": 0.85,
"competitive_landscape": 0.60,
"data_availability": 0.70,
"reproducibility": 0.62
},
"composite_score": 0.64,
"evidence_for": [
{"claim": "NfL elevation predicts rapid progression in AD and FTD", "pmid": "30522074"},
{"claim": "Synaptic loss precedes cognitive symptoms by years", "pmid": "28711827"},
{"claim": "Tau propagation inhibition is more effective early in animal models", "pmid": "29891713"},
{"claim": "Human biomarker studies suggest ~20-year preclinical window", "pmid": "29022381"}
],
"evidence_against": [
{"claim": "Point of no return is biomarker-defined, not mechanistically defined; NfL correlation with therapeutic futility unestablished", "pmid": "30522074"},
{"claim": "Animal model timelines do not scale to humans; P301S mice develop pathology in months vs hypothesized 5-15 year human window", "pmid": null},
{"claim": "Window may not close uniformly across neuronal populations and brain regions", "pmid": null}
]
},
{
"title": "Therapeutic Window Exists Through Activity-Dependent Regulation of Synaptic Vesicle Priming",
"description": "Pathological tau release occurs from hyperactive terminals undergoing excessive vesicle cycling, while baseline neurotransmission uses constitutively active pools. VAMP2/VAMP3 isoform switching or partial inhibition creates differential sensitivity. Requires 5-15% VAMP2 reduction to spare baseline transmission while blocking high-frequency-induced tau release.",
"target_gene": "VAMP2, VAMP3, Complexin-1/2, Munc13-1",
"dimension_scores": {
"evidence_strength": 0.52,
"novelty": 0.70,
"feasibility": 0.45,
"therapeutic_potential": 0.58,
"mechanistic_plausibility": 0.55,
"druggability": 0.42,
"safety_profile": 0.40,
"competitive_landscape": 0.55,
"data_availability": 0.60,
"reproducibility": 0.48
},
"composite_score": 0.52,
"evidence_for": [
{"claim": "VAMP2 is critical for tau secretion in Drosophila and mouse models", "pmid": "26330554"},
{"claim": "Neuronal activity dramatically increases tau release", "pmid": "30327317"},
{"claim": "Activity-dependent synaptic vesicle pool differences are well-characterized", "pmid": "11359921"}
],
"evidence_against": [
{"claim": "VAMP2 conditional knockout in excitatory neurons causes neurodegeneration", "pmid": "27671641"},
{"claim": "VAMP3 cannot compensate for VAMP2 in synaptic transmission", "pmid": "11891328"},
{"claim": "Activity-dependent pool distinction is unproven for tau release; same SNARE machinery used in both conditions", "pmid": "30327317"},
{"claim": "Tau uses multiple release pathways (exosomes, direct exocytosis, kiss-and-run); VAMP2 blockade may only partially reduce propagation", "pmid": "21402475"}
]
},
{
"title": "CHMP2B vs. CHMP2A Subunit Targeting Creates a Therapeutic Window in ESCRT-Dependent Tau Sorting",
"description": "CHMP2B is specifically involved in late endosomal sorting of ubiquitinated cargo while CHMP2A handles essential cytokinesis. Selective CHMP2B inhibition may theoretically spare essential ESCRT functions. ASSESSED AS FALSIFIED: CHMP2B knockout causes progressive neurodegeneration in vivo, directly contradicting therapeutic premise.",
"target_gene": "CHMP2B, CHMP2A, CHMP4B",
"dimension_scores": {
"evidence_strength": 0.32,
"novelty": 0.65,
"feasibility": 0.25,
"therapeutic_potential": 0.20,
"mechanistic_plausibility": 0.35,
"druggability": 0.30,
"safety_profile": 0.15,
"competitive_landscape": 0.50,
"data_availability": 0.55,
"reproducibility": 0.40
},
"composite_score": 0.33,
"evidence_for": [
{"claim": "CHMP2B mutations cause frontotemporal dementia through endosomal dysfunction", "pmid": "24554770"},
{"claim": "ESCRT-III components are recruited to tau aggregates", "pmid": "28800867"},
{"claim": "Tau propagation requires functional ESCRT machinery", "pmid": "31982669"}
],
"evidence_against": [
{"claim": "CHMP2B knockout mice show progressive neurodegeneration, not therapeutic benefit - THERAPEUTIC INDEX INVERTED", "pmid": "25869669"},
{"claim": "CHMP2B mutations cause FTD through gain-of-function or dominant-negative effects, not selective tau trafficking impairment", "pmid": "24554770"},
{"claim": "CHMP2B loss-of-function causes disease; cannot be therapeutically modulated without causing harm", "pmid": "25869669"},
{"claim": "Both CHMP2A and CHMP2B participate in overlapping ESCRT-III functions at late endosomes", "pmid": null}
]
}
],
"knowledge_edges": [
{"source_id": "H1-glymphatic", "source_type": "hypothesis", "target_id": "AQP4", "target_type": "gene", "relation": "enhances_tau_clearance"},
{"source_id": "H1-glymphatic", "source_type": "hypothesis", "target_id": "HCRTR1", "target_type": "gene", "relation": "indirectly_modulates"},
{"source_id": "H2-conformation", "source_type": "hypothesis", "target_id": "LRP1", "target_type": "gene", "relation": "blocks_tau_entry"},
{"source_id": "H2-conformation", "source_type": "hypothesis", "target_id": "HSPG", "target_type": "gene", "relation": "blocks_tau_entry"},
{"source_id": "H2-conformation", "source_type": "hypothesis", "target_id": "MAPT", "target_type": "gene", "relation": "targets_misfolded_conformation"},
{"source_id": "H3-critical_period", "source_type": "hypothesis", "target_id": "NfL", "target_type": "gene", "relation": "biomarker_of_window_closure"},
{"source_id": "H3-critical_period", "source_type": "hypothesis", "target_id": "MAPT-pTau217", "target_type": "gene", "relation": "biomarker_of_propagation_stage"},
{"source_id": "H4-vamp2", "source_type": "hypothesis", "target_id": "VAMP2", "target_type": "gene", "relation": "partial_inhibition_target"},
{"source_id": "H4-vamp2", "source_type": "hypothesis", "target_id": "VAMP3", "target_type": "gene", "relation": "compensatory_isoform"},
{"source_id": "H5-chmp2b", "source_type": "hypothesis", "target_id": "CHMP2B", "target_type": "gene", "relation": "FALSIFIED - causes_neurodegeneration_when_lost"},
{"source_id": "H1-glymphatic", "source_type": "hypothesis", "target_id": "H3-critical_period", "target_type": "hypothesis", "relation": "synergizes_with_as_combination_therapy"},
{"source_id": "H2-conformation", "source_type": "hypothesis", "target_id": "H1-glymphatic", "target_type": "hypothesis", "relation": "may_combine_to_reduce_inhibitor_dosing"},
{"source_id": "VAMP2", "source_type": "gene", "target_id": "MAPT", "target_type": "gene", "relation": "required_for_tau_secretion"},
{"source_id": "CHMP2B", "source_type": "gene", "target_id": "MAPT", "target_type": "gene", "relation": "involved_in_tau_endosomal_trafficking"},
{"source_id": "FSCN1", "source_type": "gene", "target_id": "MAPT", "target_type": "gene", "relation": "regulates_tau_secretion"}
],
"synthesis_summary": "The debate identified glymphatic enhancement via sleep-dependent mechanisms as the most feasible therapeutic strategy for expanding the tau propagation therapeutic window, leveraging FDA-approved orexin receptor antagonists (suvorexant, lemborexant) with established CNS penetration and safety profiles to reduce extracellular tau burden. The extracellular tau conformation hypothesis ranks second with high therapeutic index potential but faces technical challenges in achieving conformational selectivity across diverse tauopathy strains and navigating receptor redundancy. The critical period hypothesis provides essential clinical development framework, establishing biomarker-defined patient populations within the open therapeutic window, though animal-to-human temporal scaling remains problematic. The VAMP2 isoform switching hypothesis was substantially weakened by evidence that complete VAMP2 loss causes neurodegeneration, suggesting the margin between therapeutic and pathological disruption may be too narrow. The CHMP2B hypothesis is effectively falsified: its own supporting evidence demonstrates that CHMP2B loss-of-function causes progressive neurodegeneration in vivo, inverting the therapeutic index and rendering this approach contraindicated. Combination strategies targeting glymphatic clearance plus subthreshold propagation inhibitors emerge as the most promising development pathway, potentially reducing the dose of directly disruptive agents required for therapeutic effect."
}